Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

‘Reversible’ Blood Thinner May Cut Bleeding Risk

By AAAS | August 26, 2016

In an academic-industrial collaboration, researchers have developed an antibody that blocks the formation of blood clots without triggering bleeding, a serious risk associated with current blood thinners. The study was conducted in multiple animal models. Paving the way for safe use in humans one day, the authors also developed a second antibody that can rapidly reverse the drug’s effects, offering an additional safety check.

Blood clots can cause heart attack, stroke, and other heart and vascular diseases. Patients with these conditions are commonly treated with drugs that prevent blood from clotting, but carry a high risk for causing uncontrolled bleeding. Coagulation factor XIa (FXIa), a protein that plays a key role in blood clot formation, has emerged as a major drug target, but achieving FXIa-specific inhibition remains challenging. Here, Tovo David and colleagues designed an antibody that specifically binds FXIa and blocks its enzymatic activity.

The antibody staved off clotting in human blood as well as in mice and rabbits. The drug appeared safe in monkeys, which showed no signs of spontaneous bleeding even when given doses far higher than those required to prevent clotting.

Even though increased bleeding was not detected in these animal studies, because deficiency of FXI in humans can be associated with bleeding, the researchers also developed a second antibody as an antidote to rapidly reverse the anti-FXIa antibody’s activity.

With further development, the reversible FXIa-specific antibody may offer a new and potentially safer class of anticoagulant drug.

Related Articles Read More >

New dangers in the woods — and the hope that research offers us
Novel mass spectrometry solution simplifies insight gathering into macromolecular complexes
ENPICOM launches display solution to accelerate antibody selection while maximizing precision
Thermo Fisher Scientific autoimmune-testing instruments now available in the U.S.
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars